Recently, a set of small molecules that can covalently bind to the switch-I and –II pockets of mutant K-rasG12C provides the hope in treating cancers harboring oncogenic K-ras Several candidates, such as AMG510, ARS3248 and MRTX849, are generated and currently in clinical trials for treating solid tumors like pancreatic, colon and lung cancers [86]. Here, KRAS is linked to cancer.